From Citrus to API: Inside the Diosmin/Hesperidin Supply Chain

If you’ve been watching the vascular-support category, you’ve probably noticed the quiet surge in demand for Diosmin Citrus Aurantium Extract Hesperidin Pharmaceutical Chemicals API. To be honest, it’s not hype—clinicians and formulators both keep asking for consistent MPFF (micronized purified flavonoid fraction) quality. And yes, the sourcing story matters: real Citrus aurantium L., immature fruit, ethanol-water extraction, and good documentation.

What it is (and why teams pick it)

Sourced from immature Citrus aurantium L., extracted with food-grade ethanol and water, this Diosmin Citrus Aurantium Extract Hesperidin Pharmaceutical Chemicals API is positioned for venous health applications—think CVI and hemorrhoid formulations—across Rx in some markets and robust OTC/nutraceutical lines elsewhere. Many customers say micronization helps bioavailability; it seems that the finer PSD gives more predictable dissolution, batch after batch.

At-a-glance specifications

Composition (MPFF)	Diosmin ≈ 90%, Hesperidin ≈ 10% (real-world use may vary by spec)
Assay (HPLC)	Diosmin ≥ 90% (MPFF) or ≥ 95% for pure-grade diosmin, per Ph. Eur.-aligned methods
Particle Size	Micronized, D90 ≤ 10 μm (target); flow can be adjusted on request
Solvents / Residuals	Ethanol & Water; residuals controlled per ICH Q3C limits
Microbiology	TPC, Yeast/Mold, E. coli, Salmonella per USP & Ph. Eur. chapters
Status	Non-GMO, BSE/TSE Free, Non Irradiation, Allergen Free

Process flow (in short)

Materials: immature Citrus aurantium L. fruit → Milling → Ethanol/Water extraction → Purification → Optional hydrolysis/processing to diosmin-rich fraction → Micronization → Blending (to 90/10 MPFF if required) → QC release (HPLC, ICP-MS, micro) → Packaging (fiber drums, 25 kg).

Testing standards: HPLC per Ph. Eur./USP ; residual solvents per ICH Q3C; heavy metals by ICP-MS per /; micro per USP /. Typical shelf life: around 24–36 months sealed, cool & dry. Service life in finished dosage forms depends on excipients and packaging (actually, humidity control matters more than people think).

Applications and industries

• Pharma: MPFF tablets/capsules for venous insufficiency lines.
• Nutraceuticals: circulation and leg-comfort SKUs, once- or twice-daily.
• Topicals: gel/cream adjuncts (regional regs apply).
• Contract manufacturing: private label SKUs needing consistent micronized PSD.

Vendor snapshot (informal comparison)

Vendor	GMP/Certs	Lead Time	Notes
Finutra (Hebei, China)	cGMP-oriented, ISO 9001/22000; Ph. Eur./USP testing	≈ 2–4 weeks	Micronized MPFF, tight PSD control, customization
Vendor A (EU)	EU-GMP, Ph. Eur. focus	≈ 4–6 weeks	Premium pricing; smaller MOQs possible
Vendor B (IN)	WHO-GMP; USP/ICH alignment	≈ 3–5 weeks	Competitive cost; PSD may vary batch-to-batch

Field notes and case data

A European nutraceutical brand shifted to Diosmin Citrus Aurantium Extract Hesperidin Pharmaceutical Chemicals API with D90 ≤ 10 μm and reported smoother compression and ≈3–5% faster dissolution in QbD pilot runs (n=6 lots). Another client—more old-school—said, “Surprisingly, fewer weight-adjusts on the tablet press.” Not a clinical claim, just production reality.

Customization

• PSD tuning (D90 ≈ 6–20 μm) for different granulation setups.
• Assay targets: MPFF 90/10 or diosmin ≥ 95% pure grade.
• Gamma-irradiation alternatives: validated non-irradiation micro controls.
• Documentation pack: CoA, MSDS, TSE/BSE, Allergen, Non-GMO, stability dossier.

Origin: Building 23B1, No.2 Yuanboyuan St., Zhengding Area of China (Hebei) Pilot Free Trade Zone.

Quick test snapshot

Example lot (internal data): Diosmin 93.4% (HPLC), Hesperidin 6.2%, ethanol ≤ 1000 ppm, Pb/Cd/Hg/As each ≤ 0.5 ppm (ICP-MS), TPC ≤ 1000 cfu/g; conforms to Ph. Eur.-style methods. Values are indicative; check current CoA.

---

1. European Pharmacopoeia (Ph. Eur.) Monograph: Diosmin; General chapter 2.2.29 (HPLC).
2. USP–NF: Chromatography; / Elemental Impurities; / Microbiological Examination.
3. ICH Q3C (R8): Impurities—Guideline for Residual Solvents.
4. EMA/FDA guidance on API GMP expectations and stability principles (current versions).